Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?

Matsui S, Kudo A, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tanabe M.

J Cancer Res Clin Oncol. 2019 May 30. doi: 10.1007/s00432-019-02947-7. [Epub ahead of print]

PMID:
31147832
2.

The Clinical Implications of Peripancreatic Fluid Collection After Distal Pancreatectomy.

Yoshino J, Ban D, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M.

World J Surg. 2019 Apr 19. doi: 10.1007/s00268-019-05009-8. [Epub ahead of print]

PMID:
31004209
3.

A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms.

Liu B, Kudo A, Kinowaki Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Akashi T, Tanabe M.

J Gastroenterol. 2019 Mar 12. doi: 10.1007/s00535-019-01570-0. [Epub ahead of print]

PMID:
30863885
4.

Comprehensive molecular and immunological characterization of hepatocellular carcinoma.

Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S.

EBioMedicine. 2019 Feb;40:457-470. doi: 10.1016/j.ebiom.2018.12.058. Epub 2018 Dec 29.

5.

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.

Watanabe S, Shimada S, Akiyama Y, Ishikawa Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.

Int J Cancer. 2019 Jul 1;145(1):192-205. doi: 10.1002/ijc.32072. Epub 2018 Dec 30.

PMID:
30556125
6.

Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.

Akahoshi K, Ban D, Kuboki R, Oba A, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M.

J Gastroenterol Hepatol. 2019 Jun;34(6):1108-1115. doi: 10.1111/jgh.14477. Epub 2018 Oct 19.

PMID:
30242888
7.

Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms.

Kudo A, Akahoshi K, Ito S, Akashi T, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tateishi U, Tanaka S, Tanabe M.

Ann Surg. 2018 Jul 3. doi: 10.1097/SLA.0000000000002911. [Epub ahead of print]

PMID:
29979246
8.

Splenic artery as a simple landmark indicating difficulty during laparoscopic distal pancreatectomy.

Ishikawa Y, Ban D, Watanabe S, Akahoshi K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M.

Asian J Endosc Surg. 2019 Jan;12(1):81-87. doi: 10.1111/ases.12485. Epub 2018 Apr 15.

PMID:
29656597
9.

Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.

Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1155-1163. doi: 10.1007/s00432-018-2636-2. Epub 2018 Mar 30.

PMID:
29602973
10.

Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.

Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Tanabe M, Tanaka S.

Endocr Relat Cancer. 2018 Jun;25(6):619-631. doi: 10.1530/ERC-17-0328. Epub 2018 Mar 29.

PMID:
29599123
11.

Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.

Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, Matsumura S, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Suganami T, Yamaoka S, Ogawa Y, Tanabe M, Tanaka S.

Am J Pathol. 2018 May;188(5):1213-1224. doi: 10.1016/j.ajpath.2018.01.012. Epub 2018 Feb 16.

PMID:
29454748
12.

DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma.

Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Yamaoka S, Tanabe M, Tanaka S.

Sci Rep. 2018 Jan 8;8(1):106. doi: 10.1038/s41598-017-18323-9.

13.

A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.

Oba A, Kudo A, Akahoshi K, Kishino M, Akashi T, Katsuta E, Iwao Y, Ono H, Mitsunori Y, Ban D, Tanaka S, Eishi Y, Tateishi U, Tanabe M.

J Gastroenterol. 2017 Oct;52(10):1140-1146. doi: 10.1007/s00535-017-1349-7. Epub 2017 May 9.

PMID:
28488114
14.

Surgical pitfalls of jejunal vein anatomy in pancreaticoduodenectomy.

Ishikawa Y, Ban D, Matsumura S, Mitsunori Y, Ochiai T, Kudo A, Tanaka S, Tanabe M.

J Hepatobiliary Pancreat Sci. 2017 Jul;24(7):394-400. doi: 10.1002/jhbp.451. Epub 2017 May 3.

PMID:
28342263
15.

Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.

Ohata Y, Shimada S, Akiyama Y, Mogushi K, Nakao K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M, Tanaka S.

Mol Cancer Ther. 2017 Jun;16(6):1155-1165. doi: 10.1158/1535-7163.MCT-16-0728. Epub 2017 Feb 28.

16.

ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.

Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S.

J Hepatol. 2017 May;66(5):942-951. doi: 10.1016/j.jhep.2016.12.026. Epub 2017 Feb 24.

PMID:
28238438
17.

Preoperative direct bilirubin to prothrombin time ratio index to prevent liver failure after minor hepatectomy.

Furuyama T, Kudo A, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Tanaka S, Tanabe M.

J Hepatobiliary Pancreat Sci. 2016 Dec;23(12):763-770. doi: 10.1002/jhbp.400. Epub 2016 Oct 12.

PMID:
27717165
18.

Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.

Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T.

J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):480-8. doi: 10.1002/jhbp.366. Epub 2016 Jun 23.

PMID:
27247050
19.

Proteasome activity is required for the initiation of precancerous pancreatic lesions.

Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M.

Sci Rep. 2016 May 31;6:27044. doi: 10.1038/srep27044.

20.

Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm.

Katsuta E, Kudo A, Akashi T, Mitsunori Y, Matsumura S, Aihara A, Ban D, Ochiai T, Tanaka S, Eishi Y, Tanabe M.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1299-306. doi: 10.1007/s00432-016-2128-1. Epub 2016 Feb 17.

PMID:
26885661
21.

Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.

Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Yamaoka S, Tanabe M.

PLoS One. 2016 Jan 14;11(1):e0146564. doi: 10.1371/journal.pone.0146564. eCollection 2016.

22.

Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.

Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.

J Gastroenterol. 2016 Sep;51(9):910-22. doi: 10.1007/s00535-015-1159-8. Epub 2016 Jan 6.

PMID:
26739296
23.

CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells.

Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M.

Int J Oncol. 2016 Feb;48(2):657-69. doi: 10.3892/ijo.2015.3299. Epub 2015 Dec 18.

PMID:
26691441
24.

Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.

Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S.

Clin J Gastroenterol. 2015 Oct;8(5):300-5. doi: 10.1007/s12328-015-0594-7. Epub 2015 Aug 7.

PMID:
26249525
25.

The difficulty of laparoscopic liver resection.

Ban D, Kudo A, Ito H, Mitsunori Y, Matsumura S, Aihara A, Ochiai T, Tanaka S, Tanabe M, Itano O, Kaneko H, Wakabayashi G.

Updates Surg. 2015 Jun;67(2):123-8. doi: 10.1007/s13304-015-0302-7. Epub 2015 Jul 10. Review.

PMID:
26160064
26.

Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature.

Miura T, Ban D, Tanaka S, Mogushi K, Kudo A, Matsumura S, Mitsunori Y, Ochiai T, Tanaka H, Tanabe M.

Am J Surg. 2015 Sep;210(3):561-9. doi: 10.1016/j.amjsurg.2015.03.027. Epub 2015 Jun 1.

PMID:
26105803
27.

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.

Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.

Cancer Sci. 2015 Aug;106(8):1016-22. doi: 10.1111/cas.12701. Epub 2015 Jun 25.

28.

Intraoperative fluorescent cholangiography using indocyanine green for laparoscopic fenestration of nonparasitic huge liver cysts.

Kitajima T, Fujimoto Y, Hatano E, Mitsunori Y, Tomiyama K, Taura K, Mizumoto M, Uemoto S.

Asian J Endosc Surg. 2015 Feb;8(1):71-4. doi: 10.1111/ases.12137.

PMID:
25598059
29.

Favorable response after gemcitabine-radiotherapy for invasive pancreatic intraductal papillary mucinous neoplasm: a case report.

Ochiai T, Igari K, Furuyama T, Ito H, Mitsunori Y, Aihara A, Kumagai Y, Iida M, Odajima H, Tanaka S, Arii S, Yamazaki S.

Int Surg. 2013 Oct-Dec;98(4):340-5. doi: 10.9738/INTSURG-D-13-00031.1.

30.

High resectability of colorectal liver metastases with aggressive chemotherapy in the era of molecular target-based agents.

Ochiai T, Ohta K, Iida M, Kumagai Y, Mitsunori Y, Aihara A, Noguchi N, Tanaka S, Arii S, Yamazaki S.

Hepatogastroenterology. 2013 Jul-Aug;60(125):955-60. doi: 10.5754/hge121213.

PMID:
23803362
31.

Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance.

Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.

Hepatology. 2013 Apr;57(4):1436-47. doi: 10.1002/hep.26122. Epub 2013 Jan 25.

PMID:
23150500
32.

Contrast-enhanced intraoperative ultrasound for hepatocellular carcinoma: high sensitivity of diagnosis and therapeutic impact.

Mitsunori Y, Tanaka S, Nakamura N, Ban D, Irie T, Noguchi N, Kudo A, Iijima H, Arii S.

J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):234-42. doi: 10.1007/s00534-012-0507-9.

PMID:
22399158
33.

[Significance of contrast enhanced intraoperative ultrasound with Sonazoid for liver metastases from colorectal cancer].

Mitsunori Y, Kudo A, Nakamura N, Tanaka S, Arii S.

Nihon Rinsho. 2011 Apr;69 Suppl 3:320-4. Japanese. No abstract available.

PMID:
22213977
34.

Importin-α1 as a novel prognostic target for hepatocellular carcinoma.

Yoshitake K, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, Mitsunori Y, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.

Ann Surg Oncol. 2011 Jul;18(7):2093-103. doi: 10.1245/s10434-011-1569-7. Epub 2011 Feb 1.

PMID:
21286940
35.

Analogy between sphere forming ability and stemness of human hepatoma cells.

Uchida Y, Tanaka S, Aihara A, Adikrisna R, Yoshitake K, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Irie T, Kudo A, Nakamura N, Lai PB, Arii S.

Oncol Rep. 2010 Nov;24(5):1147-51.

PMID:
20878104
36.

Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography.

Arii S, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, Irie T.

Oncology. 2010 Jul;78 Suppl 1:125-30. doi: 10.1159/000315240. Epub 2010 Jul 8.

PMID:
20616594
37.

The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.

Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S.

J Hepatol. 2010 Jan;52(1):63-71. doi: 10.1016/j.jhep.2009.10.013. Epub 2009 Oct 29.

PMID:
19913935
38.

[ON THE ALKALOIDS OF LAURUS NOBILIS LINN].

TOMITA M, KOZUKA M, NAKAGAWA E, MITSUNORI Y.

Yakugaku Zasshi. 1963 Aug;83:763-6. Japanese. No abstract available.

PMID:
14087704

Supplemental Content

Loading ...
Support Center